We are live on ! Find out more
PASG icon

Passage Bio
PASG

32 hedge funds and large institutions have $13.2M invested in Passage Bio in 2025 Q3 according to their latest regulatory filings, with 8 funds opening new positions, 13 increasing their positions, 6 reducing their positions, and 15 closing their positions.

New
Increased
Maintained
Reduced
Closed

117% more repeat investments, than reductions

Existing positions increased: 13 | Existing positions reduced: 6

49.05% more ownership

Funds ownership: 2.82% → 51.87% (+49%)

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

18% less funds holding

Funds holding: 39 → 32 (-7)

47% less first-time investments, than exits

New positions opened: 8 | Existing positions closed: 15

60% less capital invested

Capital invested by funds: $33M → $13.2M (-$19.8M)

Holders
32
Holders Change
-7
Holders Change %
-17.95%
% of All Funds
0.42%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.03%
New
8
Increased
13
Reduced
6
Closed
15
Calls
$18K
Puts
–
Net Calls
+$18K
Net Calls Change
+$6K

Top Buyers

Rank Fund Capital Flow
1
LCM
Lynx1 Capital Management
Puerto Rico
+$1.12M
2
Renaissance Technologies
Renaissance Technologies
New York
+$209K
3
Squarepoint
Squarepoint
New York
+$164K
4
Vanguard Group
Vanguard Group
Pennsylvania
+$104K
5
Citadel Advisors
Citadel Advisors
Florida
+$46.7K

Top Sellers

Rank Fund Capital Flow
1
O
OrbiMed
New York
-$1.7M
2
NLVP
New Leaf Venture Partners
New York
-$261K
3
Acadian Asset Management
Acadian Asset Management
Massachusetts
-$147K
4
State Street
State Street
Massachusetts
-$62.8K
5
RC
RBF Capital
California
-$57.2K
Name Holding Trade Value Shares
Change 		Change in
Stake
JP Morgan Chase
26
JP Morgan Chase
New York
$120 +$7 +1 +7%
BNP Paribas Financial Markets
27
BNP Paribas Financial Markets
France
$96 +$7 +1 +9%
LI
28
LRI Investments
Florida
$96 +$7 +1 +9%
HI
29
Harbour Investments
Wisconsin
$24 +$21 +3 New
Northwestern Mutual Wealth Management
30
Northwestern Mutual Wealth Management
Wisconsin
$16 +$14 +2 New
State Street
31
State Street
Massachusetts
– -$62.8K -7,839 Closed
RC
32
RBF Capital
California
– -$57.2K -7,140 Closed
Northern Trust
33
Northern Trust
Illinois
– -$44.9K -5,603 Closed
Simplex Trading
34
Simplex Trading
Illinois
– -$33K -4,149 Closed
DIM
35
DLK Investment Management
California
– -$24.4K -3,050 Closed
XT
36
XTX Topco
Cayman Islands
– -$24.4K -3,044 Closed
Two Sigma Investments
37
Two Sigma Investments
New York
– -$18.9K -2,358 Closed
RWM
38
Ritholtz Wealth Management
New York
– -$10.2K -1,270 Closed
Mariner
39
Mariner
Kansas
– -$4.78K -597 Closed
TSS
40
Two Sigma Securities
New York
– -$4.69K -586 Closed
Goldman Sachs
41
Goldman Sachs
New York
– -$4.64K -580 Closed
Millennium Management
42
Millennium Management
New York
– -$4.3K -537 Closed
Raymond James Financial
43
Raymond James Financial
Florida
– -$2.56K -320 Closed
Group One Trading
44
Group One Trading
Illinois
– -$14 -2 Closed
MAWAG
45
Mid-American Wealth Advisory Group
Missouri
– -$13 -2 Closed
Carson Wealth (CWM LLC)
46
Carson Wealth (CWM LLC)
Nebraska
– +$14 +2 New
1
2

PASG Hedge Fund Activity: Q3 2025 in Review

32 of the 7,626 institutional investors tracked by Wall St. Rank reported a position in Passage Bio (PASG) for Q3 2025, worth a combined $13.2M — down 60% from $33M a quarter earlier.

Sellers outnumbered buyers: 15 funds closed out of PASG and 8 opened new positions — a net loss of 7 holders — while 6 trimmed existing stakes and 13 added.

The largest buyer was Lynx1 Capital Management, adding an estimated $1.12M. The largest seller was OrbiMed, cutting an estimated $1.7M.

  • 32 institutional investors held Passage Bio (PASG) as of Q3 2025, down from 39 in Q2 2025.
  • Funds reported $13.2M of Passage Bio stock for Q3 2025, down 60% quarter-over-quarter.
  • 8 funds opened new Passage Bio positions in Q3 2025 and 15 closed out, a net change of -7 holders.
  • The largest Passage Bio buyer in Q3 2025 was Lynx1 Capital Management, an estimated $1.12M added.
  • The largest Passage Bio seller in Q3 2025 was OrbiMed, an estimated $1.7M sold.

Based on aggregated 13F filings for Q3 2025.